Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.63
OREX's Cash to Debt is ranked higher than
72% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. OREX: 1.63 )
OREX' s 10-Year Cash to Debt Range
Min: 1.63   Max: No Debt
Current: 1.63

F-Score: 2
Z-Score: -4.53
M-Score: -0.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2493.96
OREX's Operating margin (%) is ranked lower than
55% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.92 vs. OREX: -2493.96 )
OREX' s 10-Year Operating margin (%) Range
Min: -107754.55   Max: -633.85
Current: -2493.96

-107754.55
-633.85
Net-margin (%) -2609.74
OREX's Net-margin (%) is ranked lower than
55% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. OREX: -2609.74 )
OREX' s 10-Year Net-margin (%) Range
Min: -105954.55   Max: -637.83
Current: -2609.74

-105954.55
-637.83
ROE (%) -329.64
OREX's ROE (%) is ranked lower than
56% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.33 vs. OREX: -329.64 )
OREX' s 10-Year ROE (%) Range
Min: -235.61   Max: -42.04
Current: -329.64

-235.61
-42.04
ROA (%) -67.37
OREX's ROA (%) is ranked lower than
54% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.07 vs. OREX: -67.37 )
OREX' s 10-Year ROA (%) Range
Min: -879.2   Max: -22.76
Current: -67.37

-879.2
-22.76
ROC (Joel Greenblatt) (%) -20561.09
OREX's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.20 vs. OREX: -20561.09 )
OREX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -193375   Max: -3874.08
Current: -20561.09

-193375
-3874.08
Revenue Growth (%) 10.10
OREX's Revenue Growth (%) is ranked higher than
76% of the 655 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. OREX: 10.10 )
OREX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 10.1
Current: 10.1

0
10.1
EBITDA Growth (%) -9.20
OREX's EBITDA Growth (%) is ranked higher than
59% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. OREX: -9.20 )
OREX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -8
Current: -9.2

EPS Growth (%) -10.10
OREX's EPS Growth (%) is ranked higher than
65% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. OREX: -10.10 )
OREX' s 10-Year EPS Growth (%) Range
Min: -55.4   Max: 153.4
Current: -10.1

-55.4
153.4
» OREX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

OREX Guru Trades in Q3 2013

Steven Cohen 702,500 sh (+150.89%)
RS Investment Management 1,505,785 sh (+7.35%)
John Burbank 750,000 sh (unchged)
» More
Q4 2013

OREX Guru Trades in Q4 2013

Paul Tudor Jones 11,920 sh (New)
Steven Cohen 3,998,545 sh (+469.19%)
RS Investment Management 1,930,285 sh (+28.19%)
Steven Cohen 100,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
John Burbank Sold Out
» More
Q1 2014

OREX Guru Trades in Q1 2014

RS Investment Management 2,223,585 sh (+15.19%)
Paul Tudor Jones Sold Out
Steven Cohen 676,800 sh (-83.07%)
» More
Q2 2014

OREX Guru Trades in Q2 2014

RS Investment Management 2,179,142 sh (-2%)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-12-31 Sold Out 0.15%$4.72 - $6.83 $ 4.08-27%0
John Burbank 2012-09-30 New Buy0.2%$3.77 - $7.39 $ 4.08-23%750000
George Soros 2012-06-30 Sold Out 0.03%$3.16 - $6.37 $ 4.088%0
George Soros 2012-03-31 New Buy0.03%$1.68 - $5.01 $ 4.0831%500000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 126.07
OREX's P/S is ranked higher than
50% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.81 vs. OREX: 126.07 )
OREX' s 10-Year P/S Range
Min: 12.8   Max: 633
Current: 126.07

12.8
633
EV-to-EBIT -5.19
OREX's EV-to-EBIT is ranked higher than
50% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.17 vs. OREX: -5.19 )
OREX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -5.19

Current Ratio 5.66
OREX's Current Ratio is ranked higher than
90% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. OREX: 5.66 )
OREX' s 10-Year Current Ratio Range
Min: 1.99   Max: 19.3
Current: 5.66

1.99
19.3
Quick Ratio 5.66
OREX's Quick Ratio is ranked higher than
91% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. OREX: 5.66 )
OREX' s 10-Year Quick Ratio Range
Min: 1.99   Max: 19.3
Current: 5.66

1.99
19.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.79
OREX's Price/Median PS Value is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.27 vs. OREX: 0.79 )
OREX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 4.56
Current: 0.79

0.12
4.56
Forward Rate of Return (Yacktman) -37.16
OREX's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. OREX: -37.16 )
OREX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 15.1   Max: 16.7
Current: -37.16

15.1
16.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:JXS.Germany
Orexigen Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in development of pharmaceutical product candidates for the treatment of obesity. Its product candidate includes: Contrave & Empatic.
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
Steve Cohen Bets On Orexigen Ahead of FDA Approval Jan 31 2011 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
cooldecency99 note on OREX May 01 2010 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Oct 01 2014
The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation... Sep 18 2014
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved Sep 17 2014
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference Sep 16 2014
Insider Trading Alert - HTGC, OREX And TEP Traded By Insiders Sep 16 2014
Shire eating disorder drug gets U.S. priority review Sep 15 2014
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 15 2014
Novo Nordisk's Saxenda Gets Positive Opinion for Obesity Sep 12 2014
[video] Orexigen's anti-obesity pill wins FDA Approval Sep 12 2014
[video] Orexigen drops in spite of FDA approval Sep 11 2014
How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval? Sep 11 2014
U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Sep 11 2014
Orexigen's Obesity Drug Contrave Approved by the FDA Sep 11 2014
FDA approves weight-loss drug Contrave Sep 11 2014
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised Sep 11 2014
[video] Orexigen's obesity pill Sep 11 2014
[$$] FDA Approves Weight-Loss Drug Sep 11 2014
Long-awaited diet pill gets U.S. approval Sep 11 2014
FDA approves weight-loss drug Contrave Sep 11 2014
Orexigen Therapeutics Call scheduled for 8:30 am ET today Sep 11 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK